Adverse hematological and coagulability reactions to the use of antituberculosis preparations
DOI:
https://doi.org/10.52692/1857-0011.2023.3-77.37Keywords:
hematological adverse reactions, coagulability, antituberculosis preparationsAbstract
Treatment of tuberculosis requires long-term use of antituberculosis drugs with a high risk of side effects. In recent decades, along with the frequent and detailed side effects (gastrointestinal symptoms, hepatotoxicity, neurotoxicity, allergic reactions), hematological and coagulation disorders have been described when taking antituberculosis drugs. Their main manifestations can be: iron deficiency anemia, hemolytic anemia, megaloblastic and sideroblastic anemia, thrombocytopenia, thrombocytopenic purpura, leukopenia, eosinophilia, agranulocytosis, deep vein thrombosis, thromboembolism, disseminated intravenous coagulopathy, etc. Although these side effects are rare, they require special attention because they can appear more frequently in the case of intermittent or interrupted treatment and present diagnostic difficulties.
References
Alawad M.J., Albuni M.K., Subahi E.A., Kamal I. Rifampicin-Induced Pulmonary Embolism: A Rare Side Effect. Cureus. 2021 Oct 19;13(10):e18904.
Bansal R., Sharma P.K., Sharma A. A case of thrombocytopenia caused by rifampicin and pyrazinamide. Indian J Pharmacol. 2013 Jul-Aug;45(4):405-7.
Chen G., He J.Q. Rifampicin-induced disseminated intravascular coagulation in pulmonary tuberculosis treatment: A case report and literature review. Medicine (Baltimore). 2017 Feb;96(7):e6135.
Dixit R., George J., Sharma A.K. Thrombocytopenia due to rifampicin. Lung India. 2012 Jan;29(1):90-2.
Havey T.C., Cserti-Gazdewich C., Sholzberg M. et al. Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. Am J Trop Med Hyg. 2012 Feb;86(2):264-7.
Kuwabara G., Tazoe K., Imoto W.et al. Isoniazid-induced Immune Thrombocytopenia. Intern Med. 2021 Nov 15;60(22):3639-3643.
Minardi M.L., Fato I., Di Gennaro F. et al. Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. Microorganisms. 2021 Jul 9;9(7):1477.
Nakane C., Nishimoto K., Kishimoto E. еt al. A case of severe thrombocytopenia after the first exposure to rifampicin. Respir Med Case Rep. 2023 Feb 25; 42: 101823.
Sanwal C., Kaldas A., Surani S., Bailey M. Rifampin-Induced Acute Intravascular Hemolysis Leading to Heme Pigment-Related Kidney Injury. Cureus. 2020 Jul 10;12(7):e9120.
Sousa G., Carreiro A., Duarte P. Rifampicin-induced disseminated intravascular coagulation: An antibody-mediated side effect. Pulmonology. 2021 MayJun;27(3):269-272.
Tiperneni R., Khalid F., Fichadiya H. et al. Deranged Haemostasis: Rifampin-Induced Coagulopathy. Eur J Case Rep Intern Med. 2022 May 13;9(5):003380.
Vayne C., Guéry E.A., Rollin J. et al. Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. J Clin Med. 2020 Jul 13;9(7):2212.
Vučić D., Cvitkušić-Lukenda K., Dunđer I. et al. Diagnostic complexity of rifampicin-induced coagulopathy in a patient with spontaneous muscle bleeding: A case report. Medicine (Baltimore). 2021 Jul 2;100(26):e26234.
Downloads
Published
License
Copyright (c) 2024 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
